Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27431235 | 0.81 | AAK1 (0.38) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL27937343 | 0.81 | HDAC6 (0.34) | HDAC6HDAC1HDAC2NFKB1NFKB2 | |
| SCHEMBL23564665 | 0.80 | HDAC6 (0.36) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL16932541 | 0.78 | HDAC6 (0.35) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL25913612 | 0.77 | — | — | |
| SCHEMBL27904984 | 0.77 | HDAC6 (0.34) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL8326321 | 0.77 | HDAC6 (0.34) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL953166 | 0.76 | MMP13 (0.39) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL1162878 | 0.76 | MMP13 (0.39) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL17571449 | 0.76 | HDAC6 (0.33) | AAK1MMP13HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2009-06-11 | — | — | US | disclosed |
| US-20090118271-A1 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-07 | — | — | US | disclosed |
| CN-101340913-A | Prophylactic or therapeutic agent for pancreatic cancer, ovarian cancer or liver cancer comprising novel water-soluble prodrug | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-01-07 | — | — | CN | disclosed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1925309-A1 | NOVEL ANTICANCER CONCOMITANT DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | KRAS, TOP1, ERBB3 | AAK1 2777/4885MMP13 1840/4885HDAC6 36/4885 |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | ADH1A, ADH1C, SLC43A1 | AAK1 2686/4885MMP13 1801/4885HDAC6 3509/4885 |
| US-20090118271-A1 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug | TP53, SLC10A1, BRCA1 | AAK1 2980/4885MMP13 2464/4885HDAC6 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.